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Abstract: Despite interesting properties, the use of 67Cu, 186Re and 47Sc theranostic radionuclides in
preclinical studies and clinical trials is curtailed by their limited availability due to a lack of widely
established production methods. An IAEA Coordinated Research Project (CRP) was initiated to
identify important technical issues related to the production and quality control of these emerging
radionuclides and related radiopharmaceuticals, based on the request from IAEA Member States.
The international team worked on targetry, separation, quality control and radiopharmaceutical as-
pects of the radionuclides obtained from research reactors and cyclotrons leading to preparation of
a standard recommendations for all Member States. The CRP was initiated in 2016 with fourteen
participants from thirteen Member States from four continents. Extraordinary results on the produc-
tion, quality control and preclinical evaluation of selected radionuclides were reported in this pro-
ject that was finalized in 2020. The outcomes, outputs and results of this project achieved by partici-
pating Member States are described in this minireview.
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1. INTRODUCTION
The past decade has been met with a significant growth
in 68Ga and 177Lu-radiopharmaceuticals  playing an effective
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role as an almost perfect theranostic pair. This is attributed
in  part  to  the  availability  of  commercial  generators  which
gave rise to a chemically useful [68Ga]GaCl3. As such, 
68Ga
is the first widely accessible radiometal for PET, and is nice-
ly matched with the available [177Lu]LuCl3 from research re-
actors through direct and indirect routes. However, despite
the growth in the use of 68Ga and 177Lu, the quest for addition-
al  radionuclides  for  theranostic  applications  continue  for
many reasons including:
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a longer-lived PET radionuclide to facilitate logistics
of  distribution  or  allowing  imaging  out  to  longer
time  points
a higher energy β- emitter
a shorter half-life β- emitter
a matched pair (i.e. an imaging and therapy nuclide
of the same element)
Among the several theranostic concepts, the most recent
approach includes the use of a single radionuclide, emitting
both  a  therapeutic  radiation  and  a  low-energy  gamma  ray
which could be used for dosimetric evaluation via  SPECT
process, and some of the notable radionuclides belonging to
this category are 67Cu, 186Re, and 47Sc. However, their use in
preclinical and clinical trials is curtailed by their limited avai-
lability due to a lack of widely established production meth-
ods. Based on requests from IAEA Member States on the de-
velopment and support on production and application of ra-
dionuclides and radiopharmaceuticals, an IAEA Coordinat-
ed  Research  Project  (CRP)  entitled  “  Therapeutic  Radio-
pharmaceuticals  Labelled  with  New  Emerging  Radionu-
clides (67Cu, 186Re, 47Sc” F22053) [1], was initiated in 2016
to address the need to explore the most promising methods
to  produce  the  remaining  three  nuclides.  These  nuclides
were  selected  based  on  their  theranostic  properties  (see
Table 1), their dual production routes through reactors and
cyclotrons, target availability, the potential for high specific
activity production, and, in the case of 67Cu and 47Sc, having
also matched-pair PET nuclides (e.g.60,61,64Cu and 43,44Sc) [2].
If one reviews clinical trial data on “clinicaltrials.gov”
website for use of different radioisotopes of these three nu-
clides, a growing trend in the past decade can be observed.
Most  of  such  studies  were  diagnostic  in  nature,  including
two very recent trials with 67Cu, and five clinical trials with
186Re [3] (Fig. 1).
2. THE CRP STORY
To stimulate progress in medical applications of radionu-
clides, IAEA organized a Consultants’ Meeting with the title
of “Preparation of CRP on Therapeutic Radiopharmaceuti-
cals Labelled with New Emerging Radionuclides” in Octo-
ber 2014. Several experts from Member States discussed the
important gaps in the theranostic radiopharmaceutical devel-
opments,  especially  the  need  for  new theranostic  radionu-
clides that would have extraordinary chemical, and physical
properties.  Among  the  selected  radionuclides  were  64Cu,
47Sc, 67Cu, and 186Re, with rather long half-lives, photon and
soft  beta  emission,  and  well-known  chelation  chemistry.
Due to robustness and available expertise on 64Cu, a separate
CRP was initiated on 64Cu-theranostic radiopharmaceuticals.
During 2016-2020, the CRP explored the most promis-
ing methods to produce the remaining three radionuclides.
The investigated nuclear  reactions were largely dependent
on the different types of available facilities (e.g. reactor/ac-
celerator)  and  corresponding  particle  availability,  energy
ranges, nuclear data, targetry, irradiation, purification, quali-
ty control, and in some cases radiopharmaceutical aspects.
Fig.  2  highlights  the  main  topics  investigated  during  this
CRP.
47Sc, 67Cu, and 186Re can be produced using research reac-
tors and according to the IAEA research reactor portal [4],
about 70 such facilities are currently operating worldwide.
On the other hand, these radionuclides can also be produced
with particle accelerators, including high energy proton li-
nacs, electron linacs, or/and a broad network of cyclotrons
as demonstrated in the IAEA database; Cyclotrons used for
Radionuclide Production [5]. Therefore, significant produc-
tion potential exists for most of the Member States for these
radionuclides.  Twenty-nine  proposals  to  participate  in  the
CRP were received from 13 Member States and 14 such pro-
posals were selected (two from Poland) (Table 2) based on
the quality of the proposal, available infrastructure and hu-
man resources, and thought-through workplan.
(Fig. 3) shows the worldwide distribution of Member States
working in this CRP. The participants enabled highly collab-
orative efforts leveraged by the unique expertise offered by
each  of  the  groups.  For  example,  CRP  participants  from
Egypt,  India,  Iran,  and  Poland  had  significant  experience
with  nuclide  production  with  reactors;  CRP  participants
from France, Hungary, Iran, Italy, and Malaysia had exper-
tise related to cross section measurements and/or theoretical
modelling of production yields; CRP participants from Re-
public of Korea, Iran, Poland, Syria, and USA were experi-
enced  in  target  preparation  (including  its  recycling);  CRP
participants  from  Egypt,  France,  Japan,  India,  Iran,  Italy,
Syria, Poland, and USA were experts in isotope purification
techniques; and finally CRP participants from Egypt, India,
Poland, Saudi Arabia, and USA had experience in peptide
chemistry and radiolabelling.
This article is not a full review on the worldwide situa-
tion of the radionuclide production, rather it focuses on the
work  done  by  the  CRP  participants.  For  simplicity,  this
minireview presents a summary for each radionuclide in sub-
sections of Nuclear Data,  Target Preparation, Purification,




The  production  of  no-carrier  added  67Cu  by  using  nu-
clear reactors is feasible via the 67Zn(n,p)67Cu reaction using
fast neutron fluxes (> 1 MeV) and was investigated in this
CRP. The 66Cu(n,γ)67Cu nuclear  reaction is  not  considered
favourable due to the low production yield of  67Cu in car-
ried-added form [6]. The 68Zn(n,d) reaction is also not con-
sidered favourable due to low yields.
Accelerator-based production of 67Cu has been investigat-
ed thoroughly over the last years with various reactions con-
sidered  using  Ni,  Zn  and  Ga  targets.  The  most  common
methods  include  68Zn(p,2p)67Cu,  68Zn(n,np)67Cu,  and
IAEA Activities on 67Cu, 186Re, 47Sc Current Radiopharmaceuticals, 2020, Vol. 13, No. 0   3
68Zn(γ,p)67Cu. During the CRP the production methods were
evaluated, and the most promising reactions were selected
based on the production yield, the co-production of contami-
nant  radionuclides  (in  particular  64Cu,  with  a  half  life  of
12.701 hours), and the economic feasibility [7-9]. Reactions
on nickel targets are also possible, such as 64Ni(α,p)67Cu us-
ing alpha particle accelerators.
3.2. Target Preparation
For accelerator-based production, several possible meth-
ods to prepare targets have been established, which may be
adjustable  and affordable  to  each target  system/infrastruc-
ture. Various processes are well established and practical for
cyclotron targets, such as electroplated enriched Zn target on
Fig. (1). Clinical trials starting by year as tabulated from clinicaltrials.gov for medically relevant Cu, Re, and Sc isotopes (accessed Nov.
2019). (A higher resolution / colour version of this figure is available in the electronic copy of the article).
Fig. (2). Schematic view of the items covered during the CRP on the theranostic radionuclides. (A higher resolution / colour version of this
figure is available in the electronic copy of the article).
Table 1. Physical characteristics of the CRP theranostic radionuclides.
         Radionuclide          Half-Life          β- emission          β- mean energy          Dominant γ emission          Candidate         PET nuclide(s)
         67Cu          2.58 d          100%          141 keV          185 keV (48.7%)          60Cu, 61Cu, 64Cu
         186Re          3.72 d          92.53%          346.7 keV          137 keV (9.4%)          Not suitable
         47Sc          3.35 d          100%          162.0 keV          159 keV (68.3%)          43Sc, 44Sc
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Table 2. List of institutes participating in the CRP.
Institutes Member State Radionuclide(s) Methods
Egyptian Atomic Energy Authority Egypt 47Sc Research reactor
GIP ARRONAX France 67Cu Cyclotron
Institute for Nuclear Research Hungary 186Re, 47Sc, 67Cu Nuclear calculations for cyclotrons
Bhabha Atomic Research Centre India 186Re, 47Sc, 67Cu Research reactor, Cyclotron
Nuclear Science and Technology Research institute Iran 67Cu,47Sc Research reactor, Cyclotron
Istituto Nazionale di Fisica Nucleare (INFN) Italy 67Cu,47Sc Cyclotron
National Institutes for Quantum and Radiological Science and Technology Japan 186Re,67Cu, 47Sc Cyclotron
Korea Atomic Energy Research Institute Korea (Republic of) 67Cu Cyclotron
University of Malaya Malaysia 186Re Cyclotron
National Centre for Nuclear Research & Institute of Nuclear Chemistry and
Technology Poland
67Cu, 47Sc Research reactor, Cyclotron
King Faisal Specialist Hospital and Research Centre Saudi Arabia 67Cu Cyclotron
Atomic Energy Commission of Syria (AECS) Syria 67Cu, 186Re Cyclotron
University of Alabama at Birmingham USA 47Sc Cyclotron
Fig. (3). Worldwide distribution of Member States (in blue shades) working in this CRP. (A higher resolution / colour version of this figure
is available in the electronic copy of the article).
a gold electroplated layer optimized for the specific beam en-
ergy [10].  For facilities  already using 64Ni targets  for  64Cu
and with access to alpha beams, it is possible to divert the en-
tire remote production system for 67Cu [11].
To  prepare  a  target  for  the  reactor-based  production
method, usually an appropriate amount of zinc oxide powder
(natural with 4.1% or 67Zn) is encapsulated in quartz ampule
and then placed in an aluminium irradiation container. After
performing initial quality tests, the prepared target is irradiat-
ed in nuclear reactor with fast neutrons.
3.3. Purification
67Cu extraction from the irradiated Zn target requires col-
umn chromatography, typically with anion exchange resins.
This process is well-known, however, if large amounts of Zn
need to be processed, the use of ion exchange methods may
demonstrate poor results, presumably due to overloading of
ionic  species.  To  overcome  this  challenge,  the  Japanese
group investigated a co-precipitation method using H2S and
Ag+  as  an  alternative  way  to  isolate  67Cu  from  a  bulky
amount  of  68Zn  and  other  metallic  impurities.  In  contrast,
when separating 67Cu prepared from an electroplated 64Ni tar-
get  a  well-known  procedure  was  used  as  described  in
another IAEA CRP [12] and publications [13]. Polish group
conducted studies on the potential use of solid phase extrac-
tion chromatography for Cu using a Triskem resin. The In-
dian  group  used  liquid-liquid  extraction  technique  using
dithizone as the extractant to separate 67Cu from the neutron
irradiated zinc oxide target.
3.4. Quality Control
The Chemical purity of the final product was determined
using ICP-MS methods with very high sensitivity. However,
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a quick HPLC post-column method based on ion-chromatog-
raphy was also introduced (e.g.,  Fe3+,  Cu2+,  Ni2+,  Co2+,  and
Mn2+)  by  the  Japanese  team  [14].  The  chemical  purity  of
[67Cu]CuCl2 was also determined by anodic stripping voltam-
metry  for  zinc  and  copper  impurities.  To  confirm  the  ra-
dionuclidic purity and check the potential impurities of 64Cu
and 65Zn, gamma spectroscopy methods using HPGe detec-
tors were applied. Radiochemical purity was checked using
recent published methods.
3.5. Target Recovery
Zinc recycling is a well-known process and used routine-
ly  for  67Ga production,  as  reported  in  IAEA Tec-Doc  No.
468 published in 2009 [15]. The process uses adsorption of
anionic complexes of metal ions including enriched zinc on
a  strong  acidic  cation  resin  (Dowex 1-X8 (100-200 mesh,
Cl- form), elution of other unwanted metals in anionic form,
and finally the elution of Zn. For 64Ni recovery, a method re-
ported  in  IAEA  Tec-Doc  No.  432  published  in  2004  [16]
can be applied. Alternatively, 64Ni can be recovered from the
target dissolved in hydrochloric acid aqueous solution and
treated using solvent  extraction and cation exchange resin
column chromatography [17].
3.6. Radiopharmaceutical Production
Several DOTA-based peptide radiopharmaceuticals were
studied during the CRP by groups from Japan (RGD), Saudi
Arabia and Syria (DOTATOC) which the data is under publi-
cation.  Corresponding protocols for  radiolabelling,  quality
control, and preclinical studies were developed. Two pre -
clinical  studies  were  carried  out  with  67Cu-labelled  com-
pounds in Japan [18, 11].
4. RHENIUM-186
4.1. Nuclear Data
Rhenium-186 is an interesting radionuclide, with chem-
istry which is in many ways similar to 99mTc, however with
both imaging and therapeutic capabilities the in case of 186Re
[19]. It can be produced in a research reactor using neutron
capture  on  an  enriched  185Re  target  (37.4%  natural  abun-
dance) with a large cross-section (~112 b) [20]. Alternative-
ly, it can be produced via neutron activation 187Re(n,2n)186Re
(62.6%  natural  abundance)  with  ~2b  cross  section  [21].
However, the resulting 186Re is carrier added and thus cannot
be used for high specific activity radiopharmaceuticals such
as  peptides.  Several  small  molecule  radiopharmaceuticals
which do not require high specific activity and can be manu-
factured using carrier-added 186Re (e.g., bone pain palliation
agents). Although yields are lower than reactor-based reac-
tions,  production  of  186Re  with  accelerators  (cyclotrons  or
spallation machines) can result in high specific activity no -
carrier-added 186Re suitable for targeted radiopharmaceutical
therapy although the yields are lower. The Malaysian team
evaluated the production cross-sections for 186Re via charged
particle induced reactions on W [22, 23] and identified the
186W(d,2n)186Re reaction as the cleanest production route.
4.2. Target Preparation
To  produce  186Re  in  research  reactors,  via  the
185Re(n,γ)186Re reaction,  enriched 185Re in  form of  oxide is
typically used similarly to other reactors-based metallic ra-
dionuclides already covered in IAEA Tec-Doc No. 1340 [6].
For  accelerator-based  production,  elemental  W powder  or
pressed powder in  the form of  WO3  form is  used with Cu
backings. Target recovery can be performed with ion-chro-
matography  and  electrolysis.  The  French  group  used  the
186W(d,2n)186Re reaction with deuteron energies from 3.6 to
16.6  MeV  using  tungsten  oxide  targets  [24].  The  Indian
team, on the other hand, used WO3 powder pressed this into
a grooved aluminium holder to form a pellet. The Japanese
team used the  186W powder  in  a  ceramic  (SiC)  target  box.
The  Syrian  team  used  the  186W(p,n)186Re  reaction  with  an
electroplated target fixed on a copper target holder.
4.3. Purification
The Indian team used the dissolved target for selective
electrodeposition of 186Re radionuclide from the radioactive
solution  [25].  At  the  same  time,  other  teams  used  car-
tridge-based methods. For instance, the Japanese group used
two chelating resins, while the Syrian team loaded the irradi-
ated tungsten target  solution on the preconditioned TEVA
cartridge followed by formulation in normal saline for injec-
tion.
4.4. Quality Control
Two CRP teams (India and Syria) suggested and devel-
oped a method for chemical purity determination using ICP-
AES analyses after one-month cooling time for Tungsten im-
purity detection [25]. For radionuclidic purity, the team per-
formed gamma ray spectroscopy analysis one hour after end
of processing. To test radiochemical purity, an ITLC method
was  suggested  and  successfully  applied  by  some  partici-
pants, including Japanese team.
4.5. Radiopharmaceutical Production
The most commonly used chelating agents for attaching
186Re to biomolecules are N2S2, e.g. EC, and N3S donor types
ligands, such as MAG3 [26]. The Syrian team performed pre-
paration,  quality  control,  and  evaluation  of  186Re-MDP,
186Re-HEDP. The Indian team performed 186Re-DMSA and
186Re-HEDP preparation and quality control.
5. SCANDIUM-47
5.1. Nuclear Data
Scandium-47 can be produced in a nuclear reactor and
the Indian, the Egyptian, and the Polish teams investigated
this method, specifically 46Ca(n,γ)47Ca→47Sc reaction (cross
section is 0.74 b, 46Ca natural abundance is 0.004%). Hence,
to obtain significant activity of 47Ca, target enriched in 46Ca
must  be  used  by  the  above-mentioned  reaction,  which  is
very expensive. Previously Polish group studied the neutron
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irradiation of Ti targets [27]. This method was also investi-
gated by the Egyptian team using MCNPX code to estimate
the levels of radionuclides produced during as well as post ir-
radiation and the computational results were compared with
experimental measurements.
The CRP teams also studied accelerator-based produc-
tion  of  47Sc  working  with  Ca,  Ti,  and  V targets  and  com-
pared the results. 47Sc can be also produced indirectly by be-
ta decay of 47Ca. This process requires double chemical sepa-
ration: first right after the end of irradiation (e.g. 3h), to re-
move all the Sc isotopes produced during irradiation, and se-
cond, after a few days of decay (e.g. ~ 134 h) to extract 47Sc
and stable 45Sc.
5.2. Target Preparation
For cyclotron target preparation, both CaO and elemen-
tal Ca were used. Due to established chemical handling, vari-
ous Ca targets (pressed, electro-deposited, etc.) are available
for  irradiation  at  the  respective  target  stations  including
drawer  targets,  powder  caps,  etc  [28].  The  Japanese  team
evaluated the production feasibility of 47Sc with 44CaO target
activated by alpha particles. The Iranian team used Ti tar-
gets in the form of natTi foil or by pressing the natTiO2 powder
into a pellet  which was placed into an aluminium canister
[29, 30]. The Italian team reported production of 47Sc with
natural vanadium targets [31]. The US team developed tar-
gets made both of titanium metal and titanium oxide powder
(for further details, please read “Accelerator Production of
Scandium Radionuclides: Sc-43, Sc-44g, and Sc-47” in this
thematic issue). The Polish team investigated 47Sc produc-
tion by cyclotron irradiation of 48Ca [32, 33]. The feasibility
to produce high purity 47Sc by neutron irradiation of 46Ca tar-
gets in a nuclear reactor was investigated by the teams from
Egypt [34], India, and Poland.
5.3. Purification
47Sc purification from calcium targets performed by em-
ploying  various  methods  including  filtration  of  47Sc  hy-
droxide,  extraction  from  acidic  chloride-based  solutions
with UTEVA resin extraction chromatography, and extrac-
tion  chromatography  with  tripolyphosphate  resin  or
N,N,N’,N’-tetra-n-octyldiglycolamide resin were compared
by Polish team [35]. The Egyptian team successfully report-
ed separation of the reactor produced 47Sc from natural calci-
um target using poly(acrylamide-acrylic acid)/multi-walled
carbon nanotubes composite [36], as well as the separation
of 47Sc from neutron irradiated titanium target using a novel
chitosan-acrylic  acid/multiwalled  carbon  nanotubes  com-
posite. The US team developed techniques for the dissolu-
tion of Ti metal and oxide targets and a subsequent separa-
tion based on ion exchange chromatography with branched
DGA resin, which was also performed by Italian and French
groups.
5.4. Target Recovery
To recover the target for reactor-based production, the In-
dian  team  separated  the  enriched  46Ca-amalgam  from  the
aqueous  electrolyte,  while  the  Polish  team  recovered  46Ca
via precipitation of [46Ca]CaCO3. The US team developed Ti
recycling based on a precipitation technique as well [35, 36].
5.5. Quality Control
For  accelerator-based  production,  a  protocol  for  de-
tecting other radioscandium isotopes, in particular 46Sc, was
developed using γ-spectroscopy. For reactor-based produc-
tion, the Indian and the Egyptian teams also used γ-ray spec-
trometry to verify that the levels of 47Ca present in 47Sc solu-
tion after the electrochemical separation step are permissi-
ble. To confirm the radiochemical purity, the Indian and the
Egyptian  groups  developed  ascending  paper  chromatogra-
phy using two various mobile phase systems. For chemical
purity,  the  Indian  group  determined  the  levels  of  mercury
ions  (as  well  as  Fe,  Cu,  Mn,  ion  impurities)  after  electro-
chemical separation procedure, using cold vapour-graphite
furnace atomic absorption spectroscopy (CV-GFAAS). The
Polish group extensively studied the influence of metal ions
on the Sc-labeling of DOTATATE, which can be quite use-
ful for the production of related radiopharmaceuticals [37].
All teams determined sterility and bacterial endotoxins using
well known pharmacopeia methods.
5.6. Radiopharmaceutical Production
It was suggested to evaluate the ‘practical labelling activ-
ity’  using  a  commonly  used  chelator,  such  as  DOTA esp.
DOTATATE [38], as reported by the Japanese, Polish and
the US teams. All results proved to be of good quality and
satisfactory for clinical applications that are under publica-
tion.
CONCLUSIONS AND RECOMMENDATIONS
Numerous routes have been investigated in this CRP for
producing 67Cu, 186Re, and 47Sc. This includes 67Cu produc-
tion from nickel or zinc targets, 186Re production from tung-
sten targets, and 47Sc from calcium, titanium, or vanadium
targets. Also, for 47Sc production, both the direct production
route  and  the  47Ca→47Sc  generator-like  approach  were
studied. To choose the right method for each particular Mem-
ber State, several parameters need to be considered, includ-
ing the availability of particles (e.g. n, p, α, γ) of a suitable
energy range, production yields, targetry, chemical separa-
tion methods, and radionuclidic impurities. In order to better
choose  the  production  route,  it  is  helpful  to  refer  to  the
IAEA Medical Isotope Browser tool [39].
Although the production of these radionuclides was ad-
dressed in this project, understanding the additional clinical
radiation dose arising from the impurities is important and
may involve dosimetry calculations and engaging with clini-
cians for input on acceptable specifications, etc. An addition-
al  consideration  is  the  cost  and  the  availability  of  the  en-
riched target materials which may potentially be prohibitive.
Regardless of which radionuclide a production site wishes to
work with, and which production route is selected, for clini-
cal  production,  it  is  important  to  establish  quality  control
methods. IAEA has already prepared the guidelines for the
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Member States which address quality control and assurance
of emerging radiopharmaceuticals [40].
Photonuclear production of 67Cu and 47Sc was not specifi-
cally addressed in this CRP, however it is worthwhile men-
tioning  that  this  method  is  very  promising  [41,  42]  and
IAEA has conducted activities regarding this field for possi-
ble initiation of a new CRP in the future.
Based on the results and experiments performed during
this  CRP  in  fourteen  institutions  worldwide,  a  new IAEA
Technical Document is underway to provide recommenda-
tions on production, quality control and radiopharmaceutical
production and labeling aspects of the 67Cu, 186Re, and 47Sc
theranostic radionuclides.
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N2S2 = Diamine-Dithiol
EC = Ethylene Dicysteine
N3S = Triamide-thiol
MAG3 = Mercaptoacetyl-triglycine
MDP = Methylene Diphosphonate
HEDP = Hydroxy Ethylene Diphosphonate
DMSA = Dimercapto Succinic Acid
ITLC = Instant Thin Layer Chromatography
RTLC = Radio Thin Layer Chromatography
CV-GFAAS = Cold Vapour-Graphite Furnace Atomic Absorption
Spectroscopy
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